Shanghai Hile Bio-Technology Co., Ltd.

603718

CNE1000022T4

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 30/05/2024 BST			5-day change	1st Jan Change
7.47 ^CNY	+1.77%		-1.71%	-30.25%

04-29	Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-29	Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Shanghai Hile Bio-Technology Co., Ltd. Announces Cash Dividend for 2019, Payable on July 15, 2020

July 06, 2020

Shanghai Hile Bio-Technology Co., Ltd. announced cash dividend of RMB 0.006 (taxes included) per A share for 2019. Record date is July 14, 2020. Ex-dividend date is July 15, 2020. Cash dividend payable date is July 15, 2020.

Latest news about Shanghai Hile Bio-Technology Co., Ltd.

Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23	CI
Shanghai Hile Bio-Technology Co., Ltd.(XSSC:603718) added to S&P Global BMI Index	18/09/23	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23	CI
Shanghai Zhizhuo Enterprise Management Consulting Co., Ltd. agreed to acquire Shanghai Caiyin Biotechnology Co., Ltd. from Shanghai Hile Bio-Technology Co., Ltd. for CNY 2 million.	11/04/23	CI
Shandong Sinder Technology Co., Ltd agreed to acquire Shandong Hile Biological Products Co., Ltd. from Shanghai Hile Bio-Technology Co., Ltd. for approximately CNY 110 million.	11/04/23	CI
Shanghai Hile Bio-Technology Plans to Sell Biological Products Unit	11/04/23	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	11/04/23	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	28/10/22	CI
Shandong Hile Biological Products Co., Ltd. announced that it has received CNY 140 million in funding from Shanghai Hile Bio-Technology Co., Ltd.	29/09/22	CI
Shandong Hile Biological Products Co., Ltd. announced that it expects to receive CNY 140 million in funding from Shanghai Hile Bio-Technology Co., Ltd.	29/08/22	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	29/08/22	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	28/04/22	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	29/10/21	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	27/08/21	CI
WuXi Vaccines Inc. announced that it expects to receive $136 million in funding from Shanghai Hile Bio-Technology Co., Ltd., WuXi Biologics Inc.	12/05/21	CI
Yangling Jinhai Biotechnology Co., Ltd. announced that it has received CNY 85 million in funding from Shanghai Hile Bio-Technology Co., Ltd., Shanghai Runling Investment Partnership	28/04/21	CI
Shanghai Hile Bio-Technology Co., Ltd. completed the acquisition of 40% stake in Yangling Jinhai Biotechnology Co., Ltd. from Biogenesis Bago S.A. and Biogénesis Bagó Uruguay S.A.	28/04/21	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	23/04/21	CI
WuXi Biologics Cayman : , Shanghai Hile to Restructure Vaccine JV	02/04/21	MT
Shanghai Hile Bio-Technology Co., Ltd. intends to acquire 40% stake in Yangling Jinhai Biotechnology Co., Ltd. from Biogenesis Bago S.A. and Biogénesis Bagó Uruguay S.A. for CNY 56 million.	16/03/21	CI
Yangling Jinhai Biotechnology Co., Ltd. announced that it expects to receive CNY 85 million in funding from Shanghai Hile Bio-Technology Co., Ltd., Shanghai Runling Investment Partnership	14/03/21	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	27/10/20	CI

Chart Shanghai Hile Bio-Technology Co., Ltd.

Duration

Period

Chart Shanghai Hile Bio-Technology Co., Ltd.

More charts

Company Profile

SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. is principally engaged in the research & development, production and sales of veterinary biological products. The Companyâs products mainly include escherichia coli (K88 and K99) gene modified vaccines for piglets, inactivated; porcine reproductive and respiratory syndrome vaccines, live and swine infectious atrophic rhinitis vaccines, inactivated; newcastle disease mild vaccines, living; newcastle disease, infectious bronchitis, egg drop syndromeâ76 vaccines, inactivated and infectious bronchitis vaccines, living, among others. The Company distributes its products mainly in China.

Sector

Pharmaceuticals

Calendar

28/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Veterinary Drugs

	1st Jan change	Capi.
SHANGHAI HILE BIO-TECHNOLOGY CO., LTD.	-30.25%	679M
ZOETIS INC.	-14.09%	77.37B
ELANCO ANIMAL HEALTH INCORPORATED	+18.66%	8.74B
BLUESTAR ADISSEO COMPANY	+23.75%	3.67B
VIRBAC	-1.53%	3.25B
VIMIAN GROUP AB	+16.55%	1.73B
JINYU BIO-TECHNOLOGY CO., LTD.	-16.99%	1.38B
VETOQUINOL SA	+0.98%	1.31B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-26.05%	1.24B
WUHAN KEQIAN BIOLOGY CO.,LTD	-17.86%	1.07B

Veterinary Drugs